Minimally Invasive Therapies Covidien Products Therapeutic Endoscopy Nexpowder™* Endoscopic Hemostasis System

Overview

Hemostatic powder technology that puts you in control.([FOOTNOTE=Park JS, Kim HK, Shin YW, et al. Novel hemostatic adhesive powder for nonvariceal upper gastrointestinal bleeding. Endosc Int Open. 2019 Dec; 7(12):E1763-E1767.],[ANCHOR=],[LINK=]),([FOOTNOTE=Park JS, Bang BW, Hong SJ, et al. Efficacy of a novel hemostatic adhesive powder in patients with refractory upper gastrointestinal bleeding: a pilot study. Endoscopy. 2019 May; 51(5):458-462.],[ANCHOR=],[LINK=]),([FOOTNOTE=Bang B, Lee E, Maeng J, et al. Efficacy of a novel endoscopically deliverable muco-adhesive hemostatic powder in an acute gastric bleeding porcine model. PLoS One. 2019 Jun 11; 14(6):e0216829.],[ANCHOR=],[LINK=])

The Nexpowder™* endoscopic hemostasis system is a powder that can be sprayed to an ulcer site, applying an endoscopic hemostatic agent. As a hydrophilic biocompatible adhesive material, it is composed of succinic anhydride (ε-poly-(L-lysine)) and oxidized dextran. The Nexpowder™* system forms the adhesive gel after making contact with the water or blood by reversible crosslinking. Crosslinked gel helps prevent bleeding, loss of body fluid and contamination of the ulcer site by adhering to the bleeding site in the gastrointestinal tract and then gel degrades within 1 day to 3 days.1,2,3

  • A proprietary powder coating technology that minimizes catheter clogging and particle scattering 
  • Unique delivery system that doesn’t rely on CO2 or air compressors
  • Distinctive blue color so you can have the confidence the lesion is fully covered
  • Highly adhesive gel that reacts to moisture, not just active bleeding, so it can be used in a variety of clinical applications
FEBRUARY 12-13

Endoport 2021 in Portsmouth, UK - Nexpowder™* satellite symposium presented by Dr. Rehan Haidry.

Register at this link
March 25-27

ESGE Days 2021 - "Improving the outcome and safety in hemostasis" by Prof. Pradeep Bhandari.

Register at this link

Clinical Summary

View Now

Nexpowder™* Overview

Maximum Control. Minimal Clogging.

Download Now

Product Highlights

Instructional video

Instructional video

View Now
Dr. Beyna's experience with Nexpowder™

Dr. Beyna's experience with Nexpowder™*

Watch Video
Nexpowder™ case to prevent rebleeding

Nexpowder™* case to prevent rebleeding

Watch Video

NEXPOWDER™* ENDOSCOPIC HEMOSTASIS SYSTEM WAS DEVELOPED WITH YOU AND YOUR NEEDS IN MIND

UNIQUE TECHNOLOGY, STRATEGIC PARTNERSHIP AND COMMITMENT TO ADVANCING THE PRACTICE OF THERAPEUTIC ENDOSCOPY.

Giovanni di Napoli - President of Gastrointestinal at Medtronic

Contact Us

MEDTRONIC AND NEXT BIOMEDICAL ARE PARTNERING FOR ENDOSCOPIC INNOVATION.

Dr. Don Haeng Lee - CEO at Next Biomedical, Co., LTD. Professor, Div. of Gastroenterology & Hepatology, Inha University

Contact Us

INTENDED USE

The Nexpowder™* endoscopic hemostasis system is used for most types of GI bleeding. The device is applied during an endoscopic procedure and can cover ulcer or bleeding sites. The device is not intended for use in patients with variceal bleeding.

CONTRAINDICATIONS

Because the Nexpowder™* system includes lactose, it is contraindicated in patients who have galactose intolerance, lapp lactase deficiency, or glucose-galactose malabsorption and they would be atrisk of having a nausea, bloating, and diarrhea. Because the Nexpowder™* system includes Brilliant Blue FCF, it must not be used in patients with known hypersensitivity to brilliant blue FCF.

  • ™* Third party brands are trademarks of their respective owners. All other brands are trademarks of a Medtronic company

CORPORATE RESOURCES
Minimally Invasive Therapies
Medtronic Limited

Building 9, Croxley Park

Hatters Lane

Watford, WD18 8WW

United Kingdom

©2021 Medtronic